Pfizer Inc.
Pfizer Inc. (PFE) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Pfizer Inc. (PFE), featuring income statements, balance sheets, and cash flow data.
Pfizer Inc. (PFE) Income Statement & Financial Overview
Review Pfizer Inc. PFE income statement with detailed quarterly and annual figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 |
|---|---|---|---|---|
| Revenue | $13.71B | $17.76B | $17.70B | $13.28B |
| Cost of Revenue | $2.85B | $5.91B | $6.58B | $5.04B |
| Gross Profit | $10.87B | $11.85B | $11.13B | $8.24B |
| Gross Profit Ratio | $0.79 | $0.67 | $0.63 | $0.62 |
| R&D Expenses | $2.20B | $3.04B | $2.60B | $2.68B |
| SG&A Expenses | $3.03B | $4.74B | $3.24B | $3.69B |
| Operating Expenses | $6.45B | $8.67B | $5.84B | $6.36B |
| Total Costs & Expenses | $9.29B | $13.60B | $12.42B | $11.40B |
| Interest Income | $143.00M | $170.00M | $116.00M | $130.00M |
| Interest Expense | $654.00M | $739.00M | $783.00M | $778.00M |
| Depreciation & Amortization | $1.62B | $1.79B | $1.75B | $1.73B |
| EBITDA | $5.06B | $2.52B | $7.25B | $2.40B |
| EBITDA Ratio | $0.37 | $0.14 | $0.41 | $0.18 |
| Operating Income | $4.42B | $3.19B | $5.28B | $1.88B |
| Operating Income Ratio | $0.32 | $0.18 | $0.30 | $0.14 |
| Other Income/Expenses (Net) | -$1.64B | -$3.20B | -$569.00M | -$1.98B |
| Income Before Tax | $2.79B | -$10.00M | $4.71B | -$103.00M |
| Income Before Tax Ratio | $0.20 | -$0.001 | $0.27 | -$0.008 |
| Income Tax Expense | -$189.00M | -$421.00M | $234.00M | -$134.00M |
| Net Income | $2.97B | $410.00M | $4.46B | $24.00M |
| Net Income Ratio | $0.22 | $0.02 | $0.25 | $0.002 |
| EPS | $0.52 | $0.07 | $0.79 | $0.004 |
| Diluted EPS | $0.52 | $0.07 | $0.78 | $0.004 |
| Weighted Avg Shares Outstanding | $5.67B | $5.67B | $5.67B | $5.67B |
| Weighted Avg Shares Outstanding (Diluted) | $5.71B | $5.70B | $5.71B | $5.70B |
Over the past four quarters, Pfizer Inc. demonstrated steady revenue growth, increasing from $13.28B in Q2 2024 to $13.71B in Q1 2025. Operating income reached $4.42B in Q1 2025, maintaining a consistent 32% margin over recent quarters. Despite fluctuations in R&D and SG&A expenses, EBITDA remained robust at $5.06B, reflecting operational efficiency. Net income rose to $2.97B, with EPS at $0.52. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan